Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Soluble Membrane Assault Advanced: Biochemistry and Immunobiology
The soluble membrane assault advanced (sMAC, a.okay.a., sC5b-9 or TCC) is generated on activation of complement and accommodates the complement proteins C5b, C6, C7, C8, C9 along with the regulatory proteins clusterin and/or vitronectin.
sMAC is a member of the MACPF/cholesterol-dependent-cytolysin superfamily of pore-forming molecules that insert into lipid bilayers and disrupt mobile integrity and performance. sMAC is a singular complement activation macromolecule as it’s comprised of a number of totally different subunits.
Thus far no complement-mediated perform has been recognized for sMAC. sMAC is current in blood and different physique fluids underneath homeostatic circumstances and there’s considerable proof documenting modifications in sMAC ranges throughout an infection, autoimmune illness and trauma.
Regardless of many years of scientific curiosity in sMAC, the mechanisms regulating its formation in wholesome people and its organic capabilities in each well being and illness stay poorly understood.
Right here, we assessment the structural variations between sMAC and its membrane counterpart, MAC, and look at sMAC immunobiology with respect to its presence in physique fluids in well being and illness. Lastly, we focus on the diagnostic potential of sMAC for diagnostic and prognostic functions and potential utility as a companion diagnostic.
AAV4-GFP Control Virus |
|||
| AAV-304 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 4. |
|||
AAV5-GFP Control Virus |
|||
| AAV-305 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 5. |
|||
AAV6-GFP Control Virus |
|||
| AAV-306 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 6. |
|||
scAAV1-GFP Control Virus |
|||
| AAV-331 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 1. |
|||
scAAV2-GFP Control Virus |
|||
| AAV-332 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 2. |
|||
scAAV3-GFP Control Virus |
|||
| AAV-333 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 3. |
|||
scAAV4-GFP Control Virus |
|||
| AAV-334 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 4. |
|||
scAAV5-GFP Control Virus |
|||
| AAV-335 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 5. |
|||
scAAV6-GFP Control Virus |
|||
| AAV-336 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 6. |
|||
Positive control tissue section for each antibody; Based on availability INQUIRE |
|||
| Control-Slides | Innovex | Set of 5 | EUR 211.2 |
AAV1 antibody |
|||
| 10R-2473 | Fitzgerald | 5 mL | EUR 550.8 |
|
Description: Mouse monoclonal AAV1 antibody |
|||
AAV1 ZsGreen |
|||
| 78443 | BPS Bioscience | 50 µl x 2 | EUR 545 |
|
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV1 particles constitutively express ZsGreen under a CMV promoter. ZsGreen is a human codon-optimized variant of the green fluorescent protein isolated from reef coral (Zoanthus sp). It has been engineered for higher expression in mammalian cells and is up to four times brighter than enhanced GFP (eGFP). ZsGreen expression and AAV1 transduction efficiency can easily be verified and optimized by fluorescence microscopy or flow cytometry. ZsGreen has an excitation wavelength of 493 nm and an emission wavelength of 505 nm. |
|||
AAV1 Luciferase |
|||
| 78452 | BPS Bioscience | 50 µl x 2 | EUR 545 |
|
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter. |
|||
AAV1 SaCas9 |
|||
| 78479 | BPS Bioscience | 50 µl x 2 | EUR 545 |
|
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_Cas9 is an endonuclease enzyme that introduces a double stranded break into the DNA when recruited to a specific DNA sequence by the sgRNA (single guide RNA). This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the gene._x000D_SaCas9 (Staphylococcus aureus CRISPR-associated protein 9) has demonstrated high cutting efficiency in mammalian cells, and its smaller size makes it ideal for packaging into AAV. SaCas9 recognizes a longer protospacer adjacent motif (PAM) site, 5'-NNGRRT-3', than the more traditional SpCas9 (Streptococcus pyogenes CRISPR-associated protein 9). These AAV particles constitutively express SaCas9 under the control of a CMV promoter. |
|||
AAV1 ELISA Kit |
|||
| 55R-PROPRAAV1 | Fitzgerald | 96 tests | EUR 1406.4 |
|
Description: ELISA kit for detection of AAV1 in the research laboratory |
|||
AAV1 Luciferase-eGFP |
|||
| 78461 | BPS Bioscience | 50 µl x 2 | EUR 545 |
|
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV1 particles constitutively express the firefly (Photinus pyralis) luciferase and eGFP genes connected via a T2A linker, under the control of a CMV promoter. The T2A self-cleaving peptide (derived from Thosea asigna virus 2A) leads to the efficient cleavage of the transcript, and expression of luciferase and eGFP as two separate proteins. |
|||
AAV1 Luciferase-mCherry |
|||
| 78470 | BPS Bioscience | 50 µl x 2 | EUR 545 |
|
Description: Adeno-Associated Virus serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase and mCherry genes connected via a T2A linker, under the control of a CMV promoter. The T2A self-cleaving peptide (derived from Thosea asigna virus 2A) leads to the efficient cleavage of the transcript, and expression of luciferase and mCherry as two separate proteins. |
|||
AAV2-Cre Control Virus |
|||
| AAV-310 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 2. |
|||
AAV3-Cre Control Virus |
|||
| AAV-313 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 3. |
|||
AAV4-Cre Control Virus |
|||
| AAV-314 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 4. |
|||
AAV5-Cre Control Virus |
|||
| AAV-315 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 5. |
|||
AAV6-Cre Control Virus |
|||
| AAV-316 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 6. |
|||
AAV2-Luc Control Virus |
|||
| AAV-320 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 2. |
|||
AAV3-Luc Control Virus |
|||
| AAV-323 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 3. |
|||
AAV4-Luc Control Virus |
|||
| AAV-324 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 4. |
|||
AAV5-Luc Control Virus |
|||
| AAV-325 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 5. |
|||
AAV6-Luc Control Virus |
|||
| AAV-326 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 6. |
|||
AAV2-LacZ Control Virus |
|||
| AAV-342 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 2. |
|||
AAV3-LacZ Control Virus |
|||
| AAV-343 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 3. |
|||
AAV4-LacZ Control Virus |
|||
| AAV-344 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 4. |
|||
AAV5-LacZ Control Virus |
|||
| AAV-345 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 5. |
|||
AAV6-LacZ Control Virus |
|||
| AAV-346 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 6. |
|||
AAV2 Null Control Virus |
|||
| AAV-352 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 2. |
|||
AAV3 Null Control Virus |
|||
| AAV-353 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 3. |
|||
AAV4 Null Control Virus |
|||
| AAV-354 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 4. |
|||
AAV5 Null Control Virus |
|||
| AAV-355 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 5. |
|||
AAV6 Null Control Virus |
|||
| AAV-356 | Cell Biolabs | 50 ?L | EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 6. |
|||
GFP Expressing Human Glioblastoma Cells |
|||
| TR01-GFP | Neuromics | 500,000 Cells | EUR 1624.8 |
AAV1 (intact particle) antibody |
|||
| 10R-2446 | Fitzgerald | 50 ug | EUR 699.6 |
|
Description: Mouse monoclonal AAV 1 (intact particle) antibody |
|||
pCDH-Cuo-RFP-T2A-GFP (positive control virus) |
|||
| QM350VA-1 | SBI | >1 x 10^6 IFUs | EUR 763.2 |
GFP Expressing Human Gastric Carcinoma N87 Cells |
|||
| TR02-GFP | Neuromics | 500,000 Cells | EUR 1624.8 |
GFP Expressing Human Renal Adenocarcinoma Cells (ACHN) |
|||
| TR04-GFP | Neuromics | 500,000 Cells | EUR 1624.8 |
GFP Expressing Human Prostate Carcinoma Cells (DU 145) |
|||
| TR03-GFP | Neuromics | 500,000 Cells | EUR 1624.8 |
pRedZeo-CMV Virus [positive control] |
|||
| SR10046VA-1 | SBI | >2 x 10^6 IFUs | EUR 826.8 |
pRedTK-CMV Virus [positive control] |
|||
| SR10052VA-1 | SBI | >2 x 10^6 IFUs | EUR 826.8 |
pGreenZeo-mCMV Virus [negative control] |
|||
| SR500VA-1 | SBI | >2 x 10^6 IFUs | EUR 806.4 |
pGreenZeo-CMV Virus [positive control] |
|||
| SR501VA-1 | SBI | >2 x 10^6 IFUs | EUR 806.4 |
Positive control tissue section for each individua |
|||
| Control-Slides-for-each-antibody | Innovex | Set of 25 | EUR 355 |
|
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
|||
GFP Lentivirus Control |
|||
| LTV-300 | Cell Biolabs | 1 vial | EUR 679.2 |
|
Description: HIV-1 Lentivirus |
|||
Influenza A virus HA Control/blocking peptide |
|||
| AB-23091-P | Alpha Diagnostics | 100ug | EUR 196.8 |
Vaccinia virus Complement control protein C3 (VACWR025) |
|||
| 1-CSB-YP302389VAI | Cusabio |
|
|
|
Description: Recombinant Vaccinia virus Complement control protein C3(VACWR025) expressed in Yeast |
|||
Green Fluorescent Protein (GFP-fusion protein) ELISA Kit, 96 tests, Quantitative |
|||
| 800-420-GFP | Alpha Diagnostics | 1 kit | EUR 854.4 |
pAAV-GFP Control Vector |
|||
| AAV-400 | Cell Biolabs | 10 µg | EUR 679.2 |
|
Description: Use this control vector to co-transfect along with AAV packaging vectors to produce a recombinant AAV control. |
|||
pscAAV-GFP Control Vector |
|||
| AAV-410 | Cell Biolabs | 10 µg | EUR 679.2 |
|
Description: Use this control vector to co-transfect along with AAV packaging vectors to produce a recombinant AAV control. |
|||
GFP-Control Protein Vector |
|||
| PV003 | ABM | 500 ng | EUR 224.4 |
Baboon Anti-Rabies Virus IgG antiserum negative control |
|||
| 600-070-03N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Baboon Anti-Rabies Virus IgG antiserum positive control |
|||
| 600-070-04P | Alpha Diagnostics | 1 ml | EUR 270 |
Purified Nipah virus Glycoprotein control for Western Blotting |
|||
| NIV11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Purified Nipah virus Nucleoprotein control for Western Blotting |
|||
| NIV21-C | Alpha Diagnostics | 100 ul | EUR 270 |
pGreenFire 2.0-CMV positive control virus (pGF2-CMV-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR410VA-P | SBI | >2 x 10^6 IFUs | EUR 836.4 |
pGreenFire 2.0-mCMV negative control virus (pGF2-mCMV-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR411VA-P | SBI | >2 x 10^6 IFUs | EUR 836.4 |
Human Anti-Mumps Virus (parotitis) IgG negative control serum |
|||
| 520-100-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Human Anti-Mumps Virus (parotitis) IgG positive control serum |
|||
| 520-100-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Mouse Anti-Mumps Virus (parotitis) IgG negative control serum |
|||
| 520-130-05N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Mouse Anti-Mumps Virus (parotitis) IgG positive control serum |
|||
| 520-130-06P | Alpha Diagnostics | 1 ml | EUR 270 |
Monkey Anti-Mumps Virus (parotitis) IgG negative control serum |
|||
| 520-160-03N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Monkey Anti-Mumps Virus (parotitis) IgG positive control serum |
|||
| 520-160-04P | Alpha Diagnostics | 1 ml | EUR 270 |
Rhesus Monkey Anti-Rabies Virus IgG antiserum negative control |
|||
| 600-070-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Rhesus Monkey Anti-Rabies Virus IgG antiserum positive control |
|||
| 600-070-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Monkey (Cynomolgous) Anti-Rabies Virus IgG antiserum negative control |
|||
| 600-070-05N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Cynos Monkey Anti-Rabies Virus IgG antiserum positive control |
|||
| 600-070-06P | Alpha Diagnostics | 1 ml | EUR 270 |
Camelpox virus H3L/p35 protein control for western blot |
|||
| CPOX11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Mayaro virus (MAYV) Capsid Protein control for Western Blotting |
|||
| MAYV31-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Mayaro virus (MAYV) nsP1 protein control for Western Blotting |
|||
| MAYV41-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Mayaro virus (MAYV) 6K Protein control for Western Blotting |
|||
| MAYV51-C | Alpha Diagnostics | 100 ug | EUR 343.2 |
Mayaro virus (MAYV) E3 protein control for Western Blotting |
|||
| MAYV61-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
pGreenPuro Scramble Hairpin Control - Virus (for shRNAs and miRZips) |
|||
| MZIP000-VA-1 | SBI | >1 x 10^6 IFUs | EUR 859.2 |
Control/Blocking peptide for Tobacco Mosaic Virus Movement Protein |
|||
| TMVMP11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Zika Virus prM Protein (African) control for Western blot |
|||
| ZPRM11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
pMC.CMV-GFP-SV40PolyA (positive control) |
|||
| MN601A-1 | SBI | 10 ug | EUR 882 |
GFP inducible control lentiviral particles |
|||
| LVP024 | GenTarget | 1x10e7 IFU/ml x 200ul | EUR 418.8 |
|
Description: Pre-made lentiviral particles expressing codon optimized GFP under tetracycline inducible suCMV promoter. Particles contain a blasticidin-RFP fusion dual marker under the constitutive RSV promoter. |
|||
pLenti-GFP Lentiviral Control Vector |
|||
| LTV-400 | Cell Biolabs | 100 µL | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pHT10- gfp +control VT Plasmid |
|||
| PVT5006 | Lifescience Market | 2 ug | EUR 390 |
Recombinant Polyoma Virus (KV, Pneumotropic virus) Capsid Protein 1 (VP1) control for Western blot |
|||
| KVP14-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Baboon Anti-Rabies Virus Glycoprotein (RVG) IgG antiserum negative control |
|||
| 600-180-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Baboon Anti-Rabies Virus Glycoprotein (RVG) IgG antiserum positive control |
|||
| 600-180-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Human Anti-Respiratory syncytial virus (RSV) IgG Negative Control Serum |
|||
| 510-300-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Monkey Anti-Respiratory syncytial virus (RSV) IgG Negative Control Serum |
|||
| 510-325-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Monkey Anti-Respiratory syncytial virus (RSV) IgG Positive Control Serum |
|||
| 510-325-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Mouse Anti-Respiratory syncytial virus (RSV) IgG negative control serum |
|||
| 510-345-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Mouse Anti-Respiratory syncytial virus (RSV) IgG positive control serum |
|||
| 510-345-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Simian virus 5 (starin W3) P/V Control/blocking peptide |
|||
| AB-23077-P | Alpha Diagnostics | 100ug | EUR 196.8 |
Camel Anti-Camelpox virus H3L/p35 IgG negative control serum |
|||
| AE-311170-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Camel Anti-Camelpox virus H3L/p35 IgG positive control serum |
|||
| AE-311170-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Influenza A virus (H5N1) matrix protein 2 Control/blocking peptide |
|||
| M2E15-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Influenza A virus (H1N1) matrix protein 2 Control/blocking peptide |
|||
| M2E16-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Influenza A virus (H9N2) matrix protein 2 Control/blocking peptide |
|||
| M2E17-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Bovine Lumpy skin disease virus (LSDV) control for western blot |
|||
| LSDV11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
pSIF1-H1-siLuc-copGFP Positive Transduction Control (pre-packaged virus) |
|||
| LV201B-1 | SBI | >1 x 10^6 IFUs | EUR 838.8 |
Recombinant Rat sialodacryoadenitis Virus (SDAV) nucleoprotein control for Western blot |
|||
| SDAV11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Bovine Anti-Lumpy skin disease virus (LSDV) negative control serum |
|||
| RV-500700-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Bovine Anti-Lumpy skin disease virus (LSDV) positive control serum |
|||
| RV-500700-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Rabies Virus Glycoprotein (~58 kda, RVG) control for western blot |
|||
| RBVGP11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
CMV Control lentiviral particles (GFP-Bsd) |
|||
| CMV-Null-GB | GenTarget | 1 x107 IFU/ml x 200ul | EUR 418.8 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Blasticidin fusion marker under RSV promoter. |
|||
CMV Control lentiviral particles (GFP-Puro) |
|||
| CMV-Null-GP | GenTarget | 1 x107 IFU/ml x 200ul | EUR 418.8 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Puromycin fusion marker under RSV promoter. |
|||
GFP-Null fusion control lentiviral particles |
|||
| Null-G-(Puro) | GenTarget | 1x107 IFU/ml x 200ul | EUR 418.8 |
|
Description: Pre-made GFP-Null fusion Control lentivirus containing puromycin marker. GFP fusioned with a non-targeting Null sequence for evenly fluorescent signal distribution. Virus contains a Puromycin selection marker. |
|||
EF1a Control lentiviral particles (GFP-Bsd) |
|||
| EF1a-Null-GB | GenTarget | 1 x107 IFU/ml x 200ul | EUR 418.8 |
|
Description: Negative control lentivirus contains a null spacer insert under EF1a promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Blasticidin fusion marker under RSV promoter. |
|||
EF1a Control lentiviral particles (GFP-Puro) |
|||
| EF1a-Null-GP | GenTarget | 1 x107 IFU/ml x 200ul | EUR 418.8 |
|
Description: Negative control lentivirus contains a null spacer insert under EF1a promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Puromycin fusion marker under RSV promoter. |
|||
GFP-RFP fusion control lentiviral particles |
|||
| LVP442 | GenTarget | 1x10e7 IFU/ml x 200ul | EUR 541.2 |
|
Description: Pre-made lentiviral particles expressing GFP-RFP fusion contruct under suCMV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
|||
pSMPUW-GFP-Puro Lentiviral Control Vector |
|||
| LTV-401 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
SUMO-GFP (Multi-Protease Control Protein) |
|||
| M1072-250 | Biovision | each | EUR 691.2 |
SUMO-GFP (Multi-Protease Control Protein) |
|||
| M1072-50 | Biovision | each | EUR 216 |
Baboon Anti-Rabies Virus Nucleoprotein (RV-NP) IgG antiserum negative control |
|||
| 600-660-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Baboon Anti-Rabies Virus Nucleoprotein (RV-NP) IgG antiserum positive control |
|||
| 600-660-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Monkey/Chimp Anti-Zaire Ebola virus glycoprotein (GP) IgG positive control |
|||
| AE-320650-PC | Alpha Diagnostics | 2 ml | EUR 270 |
NATtrol Zika Virus (PRVABC59), External Run Control, Medium (6 x 1.0mL) |
|||
| NATZIKV(PRV)-ERCM | Zeptometrix | 6 x 1.0mL | EUR 469.34 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Zika Virus, External Run Control, Low (6 x 1 mL) |
|||
| NATZIKV-ERCL | Zeptometrix | 6 x 1 mL | EUR 396.96 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Zika Virus, External Run Control, Medium (6 x 1 mL) |
|||
| NATZIKV-ERCM | Zeptometrix | 6 x 1 mL | EUR 469.34 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol BK Virus External Run Control, Low (6 X 1 mL) |
|||
| NATBK-ERCL | Zeptometrix | 6 X 1 mL | EUR 406.94 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol BK Virus External Run Control, Medium (6 X 1 mL) |
|||
| NATBK-ERCM | Zeptometrix | 6 X 1 mL | EUR 481.82 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
Respiratory Syncytial Virus (RSV) Rapid Test Control Pack (2 X 1.5mL) |
|||
| KZMC034 | Zeptometrix | RSV Rapid Test Control Pack | EUR 117.41 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
Recombinant Lymphocytic choriomeningitis virus (LCMV) Nucleoprotein (NP) control for Western blot |
|||
| LCMV14-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Purified Pseudorabies Virus glycoprotein B (PsRV gB) control for western blot |
|||
| PSRVGB11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Mouse Anti-Sendai/(SeV/Parainfluenza virus 1) antibody negative control serum |
|||
| SEND11-MNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Mouse Anti-Sendai/(SeV/Parainfluenza virus 1) antibody positive control serum |
|||
| SEND11-MPC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Sendai/(SeV/Parainfluenza virus 1) antibody negative control serum |
|||
| SEND12-RNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Rat Anti-Sendai/(SeV/Parainfluenza virus 1) antibody positive control serum |
|||
| SEND12-RPC | Alpha Diagnostics | 1 ml | EUR 270 |
Chicken Anti-Sendai/SeV/Parainfluenza virus 1 antibody negative control serum |
|||
| SEND13-CNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Chicken Anti-Sendai/SeV/Parainfluenza virus 1 antibody positive control serum |
|||
| SEND13-CPC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Rat sialodacryoadenitis Virus (SDAV) nucleoprotein antibody negative control serum |
|||
| SDAV11-RNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Rat Anti-Rat sialodacryoadenitis Virus (SDAV) nucleoprotein antibody positive control serum |
|||
| SDAV11-RPC | Alpha Diagnostics | 1 ml | EUR 270 |
Porcine Pseudorabies Virus glycoprotein B (PsRV gB) antibody negative control serum |
|||
| RV-400400-PNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Porcine Pseudorabies Virus glycoprotein B (PsRV gB) antibody positive control serum |
|||
| RV-400400-PPC | Alpha Diagnostics | 1 ml | EUR 270 |
Bovine Viral Diarrhea Virus 2 E2 (BVDV2E2) IgG negative control serum |
|||
| RV-500100-03N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Bovine Viral Diarrhea Virus (BVDV1-3) Erns IgG negative control serum |
|||
| RV-500200-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Bovine Viral Diarrhea Virus (BVDV1-3) Erns IgG positive control serum |
|||
| RV-500200-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Recombinant Zika Virus Envelop domain III (African) control for Western blot |
|||
| ZEND21-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Mouse Anti-Mouse Pneumonia Virus (PVM) nucleoprotein antibody negative control serum |
|||
| PVMNP11-MNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Mouse Anti-Mouse Pneumonia Virus (PVM) nucleoprotein antibody positive control serum |
|||
| PVMNP11-MPC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Mouse Pneumonia Virus (PVM) nucleoprotein antibody negative control serum |
|||
| PVMNP12-RNC | Alpha Diagnostics | 1 ml | EUR 196.8 |
Rat Anti-Mouse Pneumonia Virus (PVM) nucleoprotein antibody positive control serum |
|||
| PVMNP12-RPC | Alpha Diagnostics | 1 ml | EUR 270 |
Recombinant purified Mouse Pneumonia Virus (PVM) nucleoprotein control for Western blot |
|||
| PVMNP14-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Control siRNA Vector (pGB-control) |
|||
| 9500C-20 | Biovision | each | EUR 405.6 |
GFP inducible control lentiviral particles in PBS |
|||
| LVP024-PBS | GenTarget | 5x107 IFU/ml x 200ul | EUR 852 |
|
Description: Pre-made lentiviral particles expressing codon optimized GFP under tetracycline inducible suCMV promoter. Particles contain a blasticidin-RFP fusion dual marker under the constitutive RSV promoter, provided in PBS solution |
|||
Recombinant African Swine fever virus (ASFV) P30 protein control for western blot |
|||
| ASFV11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Bovine Viral Diarrhea Virus 1 (BVDV1) Erns Protein control for western blot |
|||
| BVDR12-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Human Anti-Tai Forest virus glycoprotein (TAFV-GP) IgG negative control serum |
|||
| AE-325620-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Human Anti-Tai Forest virus glycoprotein (TAFV-GP) IgG positive control serum |
|||
| AE-325620-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Human Anti-Vesicular Stomatitis Virus Glycoprotein, Indiana (VSVIG) IgG negative control serum |
|||
| AE-327310-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Human Anti-Vesicular Stomatitis Virus Glycoprotein, Indiana (VSVIG) IgG positive control serum |
|||
| AE-327310-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Monkey Anti-Vesicular Stomatitis Virus Glycoprotein, Indiana (VSVIG) IgG negative control serum |
|||
| AE-327320-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Monkey Anti-Vesicular Stomatitis Virus Glycoprotein, Indiana (VSVIG) IgG positive control serum |
|||
| AE-327320-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Influenza A virus (H5N1) matrix protein 2 hybrid sequence Control/blocking peptide |
|||
| M2E11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
NATtrol Epstein Barr Virus (EBV) Strain:B95-8,External Run Control-Medium(6X1mL) |
|||
| NATEBV-ERCM | Zeptometrix | 6X1mL | EUR 469.34 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Zika Virus (PRVABC59), External Run Control, Low (6 x 1.0 mL) |
|||
| NATZIKV(PRV)-ERCL | Zeptometrix | 6 x 1.0 mL | EUR 396.96 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
Mouse Anti-Lymphocytic choriomeningitis virus (LCMV) Nucleoprotein (NP) antibody negative control serum |
|||
| LCMV11-MNC | Alpha Diagnostics | 1 ml | EUR 270 |
Mouse Anti-Lymphocytic choriomeningitis virus (LCMV) Nucleoprotein (NP) antibody positive control serum |
|||
| LCMV11-MPC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Lymphocytic choriomeningitis virus (LCMV) Nucleoprotein (NP) antibody negative control serum |
|||
| LCMV12-RNC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Lymphocytic choriomeningitis virus (LCMV) Nucleoprotein (NP) antibody positive control serum |
|||
| LCMV12-RPC | Alpha Diagnostics | 1 ml | EUR 270 |
Recombinant Zaire-Ebola virus nucleoprotein (Mayinga EBOV NP) protein control for Western |
|||
| EVNP11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Peripheral blood T lymphocytosis in thymoma: an perception into the immunobiology
Function: Peripheral blood T lymphocytosis (PBTL) is a uncommon, but poorly understood manifestations of thymoma, which is postulated to be linked with autoimmune/paraneoplastic manifestations reminiscent of myasthenia gravis (MG), pure crimson cell aplasia (PRCA), and so on.; extra generally encountered on this neoplasm.
Technique: We intention to explain the flowcytometric immunophenotypic information of PBTL in a 43-year-old male; 6 months after profitable completion of chemoradiotherapy (CT/RT) for a big, invasive, and metastatic kind B1 thymoma; and current a complete assessment of all such instances reported over final 42 years (N = 21) (1977-2019).
End result: A bigger measurement of the tumors (≥ 10 cm), presence of native invasion and/or distant metastasis, and kind B (cortical or lymphocyte wealthy) histology have been extra prone to be related to PBTL.
Tumors related to MG/PRCA (N = 9/21) are inclined to have decrease PBTL in comparison with these with out such manifestations; and PBTL subsided following thymectomy with or with out CT/RT. Immunophenotypic evaluation of PB revealed a CD8 + > CD4 + mature (naïve) polyclonal T cells resembling late cortical thymocytes.
Conclusion: Thymic intratumoral microenvironment may affect prevalence PBTL that will have a pathophysiologic hyperlink to the improvement of autoimmune manifestations. Immunophenotypic traits of peripheral blood lymphoid cells needs to be the clue for correct characterization and to keep away from a misdiagnosis of a lymphoproliferative neoplasm.
Immunobiology and immunotherapy of HCC: highlight on innate and innate-like immune cells
Immune-based therapies reminiscent of immune checkpoint inhibitors have revolutionized the systemic remedy of assorted most cancers varieties. The therapeutic utility of monoclonal antibodies concentrating on inhibitory pathways reminiscent of programmed cell death-1(PD-1)/programmed cell dying ligand 1 (PD-L1) and CTLA-Four to cells of the adaptive immune system has not too long ago been proven to generate significant enchancment within the medical final result of hepatocellular carcinoma (HCC).
However, present immunotherapeutic approaches induce sturdy responses in solely a subset of HCC sufferers. Since immunologic mechanisms reminiscent of continual irritation because of continual viral hepatitis or alcoholic and nonalcoholic fatty liver illness play a vital position within the initiation, improvement, and development of HCC, it is very important perceive the underlying mechanisms shaping the distinctive tumor microenvironment of liver most cancers.
The liver is an immunologic organ with giant populations of innate and innate-like immune cells and is uncovered to bacterial, viral, and fungal antigens via the gut-liver axis. Right here, we summarize and spotlight the position of those cells in liver most cancers and suggest methods to therapeutically goal them.
We additionally focus on present immunotherapeutic methods in HCC and description latest advances in our understanding of how the therapeutic potential of those brokers is perhaps enhanced.
Immunobiology of Acquired Resistance to Ticks
Ticks are blood-sucking arthropods of nice significance within the medical and veterinary fields worldwide. They’re thought of second solely to mosquitos as vectors of pathogenic microorganisms that may trigger critical infectious issues, such as Lyme borreliosis and tick-borne encephalitis.
Laborious (Ixodid) ticks feed on host animals for a number of days and inject saliva along with pathogens to hosts throughout blood feeding. Some animal species can purchase resistance to blood-feeding by ticks after a single or repeated tick infestation, leading to decreased weights and numbers of engorged ticks or the dying of ticks in subsequent infestations. Importantly, this acquired tick resistance (ATR) can scale back the chance of pathogen transmission from pathogen-infected ticks to hosts.
That is the idea for the event of tick antigen-targeted vaccines to forestall tick infestation and tick-borne illnesses. Accumulation of basophils is detected within the tick re-infested pores and skin lesion of animals exhibiting ATR, and the ablation of basophils abolishes ATR in mice and guinea pigs, illustrating the important position for basophils within the expression of ATR.
On this assessment article, we offer a complete overview of latest advances in our understanding of the mobile and molecular mechanisms accountable for the event and manifestation of ATR, with a selected give attention to the position of basophils.
T-cell immunobiology and cytokine storm of COVID-19
2019 coronavirus illness (COVID-19) presents as a newly acknowledged pneumonia and will quickly progress into acute respiratory misery syndrome which has caused a world pandemic. Till now, no healing remedy has been strongly beneficial for COVID-19 aside from customized supportive care.
T cells and virus-specific T cells are important to guard in opposition to virus an infection, together with COVID-19. Delayed immune reconstitution (IR) and cytokine storm (CS) stay critical obstacles for the treatment of COVID-19.
Most COVID-19 sufferers, particularly amongst aged sufferers, had marked lymphopenia and elevated neutrophils, however T cell counts in extreme COVID-19 sufferers surviving the illness progressively restored later.
Elevated pro-inflammatory cytokines, significantly IL-6, IL-10, IL-2, and IL-17, and exhausted T cells are present in peripheral blood and the lungs. It means that Thymosin α1 and adoptive COVID-19-specific T cells may enhance IR whereas convalescent plasma, IL-6 blockade, mesenchymal stem cells, and corticosteroids may suppress CS.
Extra medical research on this area worldwide are urgently warranted to pave the way in which for remedy of COVID-19 sooner or later.
